European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
November 2021 at a glance: focus on prevention, comorbidities, cardiogenic shock and novel devices1427
Are left ventricular ejection fraction phenotypes meaningful in acute heart failure?242
Striving for the ‘perfect’ definition of iron deficiency in heart failure178
Reply to ‘Morphine use in acute cardiogenic pulmonary oedema: is MIMO trial enough to change practice?’137
Letter regarding the article ‘Natural history and prognostic significance of iron deficiency and anaemia in ambulatory patients with chronic heart failure’134
Improving renal function during diuresis: useful information or just noise?130
120
Corrigendum to ‘Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy’ [Eur J Heart Fail117
Identifying reliable biomarkers for pulmonary congestion: Toward a close yet sustainable heart failure follow‐up111
Effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum in PARAGON‐HF108
Applying the ‘touch‐and‐go’ concept to mineralocorticoid receptor antagonists: A paradigm shift in routine heart failure management107
Heart failure: age is no excuse for complacency100
Dissecting the heart failure phenotype through phenomics98
Reply to the letter regarding the article ‘Are mechanical circulatory supports the forgotten aspect in the implementation of therapies for heart failure?’96
Issue Information96
Adrenomedullin as a marker of hypoxia, not hypoperfusion. Letter regarding the article ‘Biologically active adrenomedullin as a marker for residual congestion and early rehospitalization in patients h94
Cardiovascular magnetic resonance‐estimated pulmonary capillary wedge pressure, congestion markers, and effect of empagliflozin in patients with heart failure with reduced ejection fraction91
Abstract90
Tafamidis in patients with severe heart failure due to transthyretin amyloidosis cardiomyopathy: Improved long‐term survival89
Culture, ethnicity, and socio‐economic status as determinants of the management of patients with advanced heart failure who need palliative care: A clinical consensus statement from the Heart Failure 89
Finerenone, chronic obstructive pulmonary disease, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS‐HF trial86
Effects of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS‐HF and RALES84
Similarities and distinctions between acetazolamide and sodium–glucose cotransporter 2 inhibitors in patients with acute heart failure: Key insights into ADVOR and EMPULSE82
Rationale and design of the ESC Heart Failure III Registry – Implementation and discovery73
Association between liver fibrosis, plasma volume status, and cardiovascular mortality: The Hiroshima Study on Glucose Metabolism and Cardiovascular Diseases68
Risk factors for the development of heart failure in patients with or without prior myocardial infarction64
Simultaneous or rapid sequence initiation of medical therapies for heart failure: seeking to avoid the case of ‘too little, too late’63
Characteristics and outcomes of patients with a history of cancer recruited to heart failure trials63
Salt repletion and diuretic response: The role of serum chloride. A post‐hoc analysis of the SALT‐HF trial on furosemide and hypertonic saline solution administration in ambulato62
Vericiguat Global Study in Participants with Chronic Heart Failure: Design of the VICTOR trial60
Time‐varying analyses of survival and outcomes in patients with HeartMate 3 left ventricular assist devices60
Efficacy and safety of vericiguat in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan: insights from the VICTORIA trial60
Incidence and predictors of weaning failure from veno‐arterial extracorporeal membrane oxygenation therapy in patients with cardiogenic shock59
Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant‐level pooled analysis from the DAPA‐HF and DELIVER trials58
Left ventricular volume and maximal functional capacity in heart failure with preserved ejection fraction: Size matters58
Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians57
Issue Information56
Exercise catheterization in adults post‐Fontan with normal and abnormal haemodynamic criteria: Insights into normal Fontan physiology56
Burst steroid therapy for acute heart failure: The CORTAHF randomized, open‐label, pilot trial56
Percutaneous repair of moderate‐to‐severe or severe functional mitral regurgitation in patients with symptomatic heart failure: Baseline characteristics of patients in the RESHAPE‐HF2 trial55
Cardiac remodelling – Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology54
Issue Information53
Predicting worsening heart failure with preserved ejection fraction from non‐invasive exercise testing52
The dangerous liaison between epicardial adipose tissue and heart failure with preserved ejection fraction52
July 2023 at a glance: heart failure with preserved ejection fraction and comorbidities52
Indexing left ventricular end‐systolic dimension to body size: Association with mortality in patients with degenerative mitral regurgitation51
Issue Information51
Reply to ‘A clinical classification method with outstanding advantages for quickly identifying hazardous types’51
December 2021 at a glance: focus on medical treatment, valvular heart disease and prognostic models50
Pathophysiological pathways related to high plasma growth differentiation factor 15 concentrations in patients with heart failure50
50
Aortic valve disease and heart failure with mildly reduced ejection fraction: New insights and pending questions50
Guidance on the management of left ventricular assist device (LVAD) supported patients for the non‐LVAD specialist healthcare provider: executive summary50
0.14919185638428